Juluca is owned by Viiv Hlthcare.
Juluca contains Dolutegravir Sodium; Rilpivirine Hydrochloride.
Juluca has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Juluca are:
Juluca was authorised for market use on 21 November, 2017.
Juluca is available in tablet;oral dosage forms.
Juluca can be used as treatment of hiv infection.
The generics of Juluca are possible to be released after 24 January, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8080551 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(2 months from now) | |
US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(2 years from now) | |
US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
US10426780 | VIIV HLTHCARE | Antiviral therapy |
Jan, 2031
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101629 | VIIV HLTHCARE | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(5 months ago) |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 November, 2017
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic